Gastroenterology Research and Practice / 2013 / Article / Fig 6

Research Article

Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy In Vitro and In Vivo

Figure 6

Motility of MHCC97H cells was inhibited by NET-1shRNA and sorafenib. (a) Trans-well chamber showed the permeation amounts of MHCC97H cells after 48 h of NET-1shRNA transfection or sorafenib treatment. (b) Trans-well chamber assay suggested the permeation amounts of MHCC97H cells in NET-1shRNA, sorafenib, and combination NET-1shRNA with sorafenib and untreated cells groups were 83.67 ± 6.03, 83.33 ± 10.01, 50.33 ± 4.73, and 197.00 ± 6.00, respectively. ( represents compared with untreated group. * represents compared with combination group).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.